Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Laura M Dember, MD

Laura M Dember, MD

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Renal-Electrolyte and Hypertension Division
University of Pennsylvania Perelman School of Medicine
Center for Clinical Epidemiology and Biostatistics
Blockley Hall, Office 920
423 Guardian Drive
Philadelphia, PA 19104
Office: 215-573-5264
Fax: 215-615-0349
Education:
B.A.
Yale College, New Haven, CT, 1984.
M.D.
Yale School of Medicine, New Haven, CT, 1988.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Description of Clinical Expertise

Dr. Dember has more than 20 years of experience as a general nephrologist and has internationally-recognized expertise in the systemic amyloidoses, a group of rare disorders that often affect the kidneys. She is a member of the University of Pennsylvania multidisciplinary amyloidosis program that evaluates and treats patients with all types of amyloidosis.

Description of Other Expertise

Dr. Dember is a Co-Editor of the American Journal of Kidney Diseases and she has served on multiple NIH grant review panels and committees of the American Society of Nephrology.

Description of Research Expertise

Dr. Dember conducts patient-oriented research including mechanistic studies and clinical trials in chronic kidney disease and end-stage renal disease (ESRD). She has particular interests in hemodialysis vascular access and interventions to improve clinical outcomes in end-stage renal disease. Her research is funded by the National Institutes of Health. Dr. Dember is Principal Investigator for the Data Coordinating Center of the NIDDK Hemodialysis Novel Therapies Consortium which is conducting early phase clinical trials targeting ESRD-associated inflammation and cardiovascular disease, and she is the Principal Investigator for the "TiME Trial", a large, pragmatic cluster-randomized clinical trial being conducted through the NIH Health Care Systems Research Collaboratory. The TiME Trial has enrolled 6800 participants at more than 250 dialysis units throughout the United States and uses highly centralized implementation and data collection approaches that leverage the infrastructure and clinical care delivery systems of dialysis provider organizations. Dr. Dember is also a principal investigator for the NIDDK Hemodialysis Fistula Maturation Study -- an observational cohort study designed to elucidate predictors and mechanisms of arteriovenous fistula maturation, and she is a member of the Scientific and Data Coordinating Center for the NIDDK Chronic Renal Insufficiency Cohort Study.

Selected Publications

Dember LM, Archdeacon P, Krishnan M, Lacson E, Ling SM, Roy-Chaudhury P, Smith KA, Flessner MF: Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative. J Am Soc Nephrol Jul 2016 Notes: Epub ahead of print.

Allon M, Greene T, Dember LM, Vita JA, Cheung AK, Hamburg NM, Imrey PB, Kaufman JS, Robbin ML, Shiu Y-T, Terry CM, Umphrey HR, Feldman HI: Association between Preoperative Vascular Function and Postoperative Arteriovenous Fistula Development. J Amer Soc Nephrol May 2016.

Tachibana C, Johnson KE, Coronado GD, Dember LM, Glasgow RE, Huang SS, Martin PJ, Richards J, Rosenthal G, Septimus E, Simon GE, Solberg L, Suls J, Thompson E, Larson EB : A guide to research partnerships for pragmatic clinical trials. BMJ 349: g6826, 2014.

Terry CM, Dember LM: Novel Therapies for Hemodialysis Vascular Access Dysfunction. Clin J Am Soc Nephrol 8: 2202-12, 2013.

Peden EK, Leeser DB, Dixon BS, El-Khatib MT, Roy-Chaudhury P, Lawson JH, Menard MT, Dember LM, Glickman MH, Gustafson PN, Blair AT, Magill M, Franano FN, Burke SK. : A multi-center, dose-escalation study of human type 1 pancreatic elastase (PRT-201) administered after arterovenous fistula creation. J Vasc Access 14(2): 143-51, 2013.

Dember LM: Fistulas first - But can they last? Clin J Am Soc Nephrol 6(13): 463-4, Mar 2011.

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M : Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood Page: {Epub ahead of print] 2011.

Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR, Martin KJ, McNei JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI, Dialysis Access Consortium (DAC) Study Group: Effect of dipyridamole plus aspirin on hemodialysis graft patency N Engl J Med 360: 2191-2201, 2009.

Dember LM, Beck GJ, Allon M, Delmez J, Dixon BS, Greenberg A, Himmelfarb J, Vazquez VA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI. Dialysis Access Consortium (DAC) Study Group: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized, controlled trial. JAMA 299: 2164-71, 2008.

Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butriemene I, Livneh A, Lesnyak O, puechal X, Lachmann H, Obici L, Balshaw R, Garceau D, Hauck W. Skinner M: Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356: 2349-60, 2007.

back to top
Last updated: 07/22/2016
The Trustees of the University of Pennsylvania